Ms4322 is a PROTAC drug based on VHL, which can highly selectively reduce PRMT5 in breast cancer, cervical cancer, lung cancer, leukemia cells, and ER+ breast cancer cells and inhibit the growth of cancer cells. Here, PRMT5 is linked to cancer.